Trial Profile
A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Exposure-Response Relationship Between Abemaciclib and QT Interval in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Loperamide
- Indications Breast cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 24 Mar 2018 Results evaluating the exposure response (ER) relationship between abemaciclib and QT, presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Mar 2018 Results evaluating the two-way PK drug interaction between single doses of Loperamide 8 mg and abemaciclib 400 mg presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 11 Aug 2016 Status changed from recruiting to completed.